ArticlePloS one2011
BRAF V600E mutations are common in pleomorphic xanthoastrocytoma: diagnostic and therapeutic implications.
Article in PloS one, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 139 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
139 citing papers in PubMed, 1 synthesis or guideline pooled it, 308 citations in OpenAlex.
- BRAF Mutation is Associated with an Improved Survival in Glioma-a Systematic Review and Meta-analysis.Molecular neurobiology · 2018Pooled it
- Phase II study of vemurafenib in children and young adults with tumors harboring BRAF V600 mutations: NCI-COG pediatric MATCH trial (APEC1621) Arm G.The oncologist · 2024Trial
- BRAF Inhibition inJournal of clinical oncology : official journal of the American Society of Clinical Oncology · 2018Trial
- Intraoperative mass spectrometry mapping of an onco-metabolite to guide brain tumor surgery.Proceedings of the National Academy of Sciences of the United States of America · 2014Trial
- Sox2 protein stability is enhanced by BRafV600E and Pten deletion in adult neural stem/progenitor cells.NPJ precision oncology · 2026Article
- Identification of BRAF V600E Mutation in Cerebrospinal Fluid Aids in Diagnosing Leptomeningeal Carcinomatosis Arising From Pleomorphic Xanthoastrocytoma: A Case Report.Cancer reports (Hoboken, N.J.) · 2026Article
- Intraventricular Trigone Pleomorphic Xanthoastrocytoma: A Rare Presentation with Favorable Prognosis in a Young Adult-A Case Report.Asian journal of neurosurgery · 2025Article
- Thalamic pleomorphic xanthoastrocytoma central nervous system World Health Organization grade 3.Radiology case reports · 2025Article
- Papillary craniopharyngioma management in the era of BRAF and MEK inhibition.Journal of neuro-oncology · 2025Article
- Clinicopathological analysis of BRAF and non-BRAF MAPK pathway-altered gliomas in paediatric and adult patients: a single-institution study of 40 patients.Journal of clinical pathology · 2025Article
- Clinical outcomes for pleomorphic xanthoastrocytoma patients.Neuro-oncology practice · 2025Article
- Successful response in advanced leptomeningeal disease from pleomorphic xanthoastrocytoma with BRAF/MEK inhibitors: a case report.Frontiers in oncology · 2025Article
- Systematic characterization of antibody-drug conjugate targets in central nervous system tumors.Neuro-oncology · 2024Article
- Pediatric-Like Brain Tumors in Adults.Advances and technical standards in neurosurgery · 2024Review
- Diagnostic Insights into Pediatric Pleomorphic Xanthoastrocytoma through DNA Methylation Class and Pathological Diagnosis Analysis.Diagnostics (Basel, Switzerland) · 2023Article
- Establishment and characterization of patient-derived xenograft of a rare pediatric anaplastic pleomorphic xanthoastrocytoma (PXA) bearing a CDC42SE2-BRAF fusion.Scientific reports · 2023Article
- Diffusely Infiltrating Gliomas With Poor Prognosis,Neurosurgery practice · 2023Article
- Conventional and emerging treatments of astrocytomas and oligodendrogliomas.Journal of neuro-oncology · 2023Review
- Metabolic Rewiring in Adult-Type Diffuse Gliomas.International journal of molecular sciences · 2023Review
- Glioma: bridging the tumor microenvironment, patient immune profiles and novel personalized immunotherapy.Frontiers in immunology · 2023Review
79 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 5 institutions in 1 country.
Funding
Abstract
Pleomorphic xanthoastrocytoma (PXA) is low-grade glial neoplasm principally affecting children and young adults. Approximately 40% of PXA are reported to recur within 10 years of primary resection. Upon recurrence, patients receive radiation therapy and conventional chemotherapeutics designed for high-grade gliomas. Genetic changes that can be targeted by selective therapeutics have not been extensively evaluated in PXA and ancillary diagnostic tests to help discriminate PXA from other pleomorphic and often more aggressive astrocytic malignancies are limited. In this study, we apply the SNaPshot multiplexed targeted sequencing platform in the analysis of brain tumors to interrogate 60 genetic loci that are frequently mutated in 15 cancer genes. In our analysis we detect BRAF V600E mutations in 12 of 20 (60%) WHO grade II PXA, in 1 of 6 (17%) PXA with anaplasia and in 1 glioblastoma arising in a PXA. Phospho-ERK was detected in all tumors independent of the BRAF mutation status. BRAF duplication was not detected in any of the PXA cases. BRAF V600E mutations were identified in only 2 of 71 (2.8%) glioblastoma (GBM) analyzed, including 1 of 9 (11.1%) giant cell GBM (gcGBM). The finding that BRAF V600E mutations are common in the majority of PXA has important therapeutic implications and may help in differentiating less aggressive PXAs from lethal gcGBMs and GBMs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.